Positive thyroid cancer scintigraphy using technetium-99m methoxyisobutylisonitrile

被引:38
作者
Nemec, J
Nyvltova, O
Blazek, T
Vlcek, P
Racek, P
Novak, Z
Preiningerova, M
Hubackova, M
Krizova, M
Zimak, J
Bilek, R
机构
[1] Clinic of Nuclear Medicine, Charles' University, Institute of Endocrinology
来源
EUROPEAN JOURNAL OF NUCLEAR MEDICINE | 1996年 / 23卷 / 01期
关键词
methoxyisobutylisonitrile; sestamibi; thyroid imaging; thyroid cancer; distant metastases;
D O I
10.1007/BF01736992
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The aim of the study was to evaluate the possibility of detecting thyroid cancer recurrences without the need for withdrawal of thyroid suppressive treatment, Upper-body or whole-body scintigraphy was performed in a group of 200 patients evaluated for differentiated thyroid cancers in 1993 and 1994 using technetium-99m sestamibi. Scans were performed 20-30 min following i.v. administration of 500 MBq of Tc-99m-methoxyisobutylisonitrile (MIBI). Bone and lung metastases were detected with very high sensitivity and specificity, with a very high predictive value of negative results and a somewhat lower predictive value of positive results. The sensitivity and specificity of findings in the neck were lower but the predictive value of negative results was high, Whole-body scans with Tc-99m-MIBI are a useful tool in the follow-up of patients with differentiated thyroid cancer, for the detection of distant metastatic lesions.
引用
收藏
页码:69 / 71
页数:3
相关论文
共 10 条
  • [1] BRIELE B, 1991, NUKLEARMED, V30, P115
  • [2] HAMANN A, 1994, EUR J NUCL MED, V21, P866
  • [3] KAO CH, 1993, J NUCL MED, V34, P71
  • [4] MORIYA E, 1994, J NUCL MED, V35
  • [5] NAUREA S, 1994, J NUCL MED, V35
  • [6] NEMEC J, 1979, J NUCL MED, V20, P92
  • [7] NEMEC J, 1995, NUCL MED COMMUN, V16, P694
  • [8] Sundram F. X., 1993, Annals Academy of Medicine Singapore, V22, P557
  • [9] Vattimo A, 1992, J Nucl Biol Med, V36, P315
  • [10] YEN TC, 1994, EUR J NUCL MED, V21, P980